NKX2-1 and lung adenocarcinoma: In 2023, Ebisudani tested C59, a novel porcupine inhibitor, for Wnt-targeted therapeutic efficacy in an NKX2-1-deficient lung adenocarcinoma chip (Ebisudani et al., 2023).